# ACCESS2 Stakeholder Walkthrough Feedback And Go/No-Go Note

## Purpose

This note records the first stakeholder walkthrough feedback checkpoint for the current ACCESS2 demo package. It is a documentation record only. It does not approve production mutation, staging mutation, Railway mutation, new runtime behavior, or architecture changes.

## Walkthrough Record

- Walkthrough date: May 18, 2026.
- Walkthrough version: v1.
- Audience/stakeholder type: initial stakeholder walkthrough; specific stakeholder role was not separately recorded.
- Supporting screen prints: `ACCESS2_walkthrough_1.gdoc`.

## What Was Demonstrated

- The ACCESS2 stakeholder walkthrough v1 script was executed.
- The walkthrough used the current demo package and printable walkthrough guide.
- The demonstrated story remained within the current release posture:
  - V1 production is a read-only demo.
  - V2 correction-loop mutation remains localhost-only.
  - Staging mutation remains deferred until isolated staging or preview infrastructure is explicitly approved.

## What Landed Well

- The walkthrough completed and everything looked good.
- No specific UI, copy, workflow, or proof-chain issues were reported.

## What Caused Confusion

- No concrete confusion was reported.
- Context note: this was net-new for the audience, and no one had a prior expectation for what the UI should look like.

## Objections Or Risks Raised

- No objections were reported.
- No new risks were raised.

## Follow-Up Questions

- No follow-up questions were recorded.

## Go/No-Go Recommendation

Recommendation: go for continued stakeholder walkthrough use of the current ACCESS2 demo package in its existing safety posture.

This is not a blanket product approval and does not authorize production mutation, staging mutation, Railway mutation, or broader V2 expansion. It only indicates that the v1 walkthrough package is acceptable to keep using for additional stakeholder review unless future feedback identifies a concrete blocker.

## Recommended Next ACCESS2 Slice

Recommended next slice: run another stakeholder walkthrough using the same package and capture structured feedback, especially around:

- Whether the chronic-care outcome accountability story is clear.
- Whether the immutable review packet and audit bundle explanation is clear.
- Whether the V1 read-only versus V2 localhost-only boundary is clear.
- Whether any stakeholder asks for staging, workflow mutation, EHR/FHIR, billing, AI, or admin capabilities.

If the next walkthrough remains clear, keep the current package stable. If specific confusion appears, use a small docs/copy clarity slice rather than changing product behavior.

## July MVP Stakeholder Feedback And Go/No-Go Capture

Use this section for the July MVP package walkthrough that connects the V1 production read-only demo, V2 localhost-only correction-loop narrative or rehearsal, and local external CSV dry-run validation. This is a feedback and decision record only. It does not authorize staging, production mutation, real PHI, CMS production submission, FHIR/EHR integration, claims ingestion, billing automation, AI features, or new product scope.

### Walkthrough Date / Checkpoint

- Date:
- Checkpoint name:
- Presenter/operator:
- Package version or docs reviewed:

### Audience / Persona

- Stakeholder role or audience type:
- Primary decision lens: executive overview / clinical workflow / payer or partner fit / audit readiness / engineering handoff / other.
- Prior ACCESS2 context: none / prior V1 demo / prior V2 local demo / prior July MVP planning review.

### V1 Production Read-Only Demo Feedback

- Was it clear what can be shown now in production?
- Was it clear that V1 production is synthetic/demo data only?
- Was it clear that production remains read-only and does not expose live approval, rejection, assignment, override, or snapshot creation controls?
- Was the evidence-to-audit-bundle story understandable?
- Confusion, objections, or requested copy clarification:

### V2 Localhost-Only Correction-Loop Feedback

- Was it clear that V2 mutation remains localhost-only?
- Was it clear that the correction loop uses disposable synthetic local data?
- Was it clear that rejected snapshots remain preserved/read-only history and are not rewritten?
- Was it clear that corrected evidence creates a corrected/new immutable snapshot and only the corrected latest snapshot proceeds to approval?
- Was `audit_bundle.available=true` clear as the handoff point?
- Confusion, objections, or requested copy clarification:

### CSV Dry-Run Validation Feedback

- Was it clear that CSV intake is currently local dry-run/no-write validation only?
- Was it clear that the sample fixture is synthetic and contains no real PHI?
- Was it clear that accepted dry-run rows do not create patient, evidence, review packet, audit bundle, database, API, or frontend state?
- Was it clear that CSV intake is not FHIR/EHR integration, CMS production submission, claims ingestion, or billing automation?
- Confusion, objections, or requested copy clarification:

### Questions / Objections

- Questions asked:
- Objections or risks raised:
- Requests for staging, production mutation, real PHI, CMS submission, FHIR/EHR integration, claims ingestion, billing automation, AI, admin features, or override approval:

### Decision-Useful Feedback

- What landed well:
- What was unclear enough to affect stakeholder confidence:
- What evidence or documentation would improve a partner/pilot conversation:
- What can remain unchanged for July MVP:

### July Must-Fix Items

Record only items needed for credible July MVP or pilot-positioned walkthrough readiness. Do not treat future platform requests as July must-fix items unless they block the MVP story.

- Must-fix item:
- Owner:
- Required by:
- Evidence needed for closure:

### Future Production Hardening Items

Record items that belong after July MVP or require separate approval.

- Production mutation governance:
- Compliance/security/data-use approval for real PHI:
- Isolated staging or preview environment:
- FHIR/EHR integration:
- CMS production submission:
- Claims ingestion or billing automation:
- Operational support, monitoring, and reset/reseed ownership:

### Go/No-Go Recommendation

- Recommendation: go / conditional go / no-go for continued July MVP stakeholder walkthrough use.
- Reason:
- Conditions or blockers:
- Explicit non-authorization: this recommendation does not approve staging, production mutation, real PHI, CMS production submission, FHIR/EHR integration, claims ingestion, billing automation, AI features, or new product scope.

## Reusable Walkthrough Feedback Capture

Use this short capture block for the next stakeholder walkthrough. Keep answers concrete and do not treat requests for new capabilities as approval to build them.

- Walkthrough date:
- Stakeholder role or audience type:
- Demo path used: V1 production read-only only / V1 plus V2 localhost narrative / V1 plus V2 localhost live demo.
- What landed well:
- What caused confusion:
- Objections or risks raised:
- Follow-up questions:
- Was the V1 production read-only boundary clear?
- Was the V2 localhost-only mutation boundary clear?
- Was immutable review-packet history clear?
- Was audit bundle or manifest verification clear?
- Any requests for staging, production mutation, EHR/FHIR, billing, AI, admin features, or override approval:
- Recommended next docs/copy clarification, if any:
- Go/no-go recommendation for continued stakeholder walkthrough use:

## Safety Confirmation

- Production remained read-only.
- V2 mutation remained localhost-only.
- No production mutation testing was requested or run.
- No staging mutation testing was requested or run.
- No Railway mutation was requested or run.
- No real PHI, secrets, EHR/FHIR integration, billing integration, AI features, broad UI redesign, admin features, or override approval work was introduced.
- Immutable review packet snapshot assumptions remain preserved.
